XML 51 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $)
In Millions, except Per Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Jul. 01, 2012
Jul. 03, 2011
Jul. 01, 2012
Jul. 03, 2011
Revenues $ 15,057 $ 16,485 $ 29,942 $ 32,509
Costs and expenses:        
Cost of sales 2,752 [1] 3,571 [1] 5,497 [1] 7,040 [1]
Selling, informational and administrative expenses 3,977 [1] 4,800 [1] 7,954 [1] 9,178 [1]
Research and development expenses 1,699 [1] 2,231 [1] 3,753 [1] 4,311 [1]
Amortization of intangible assets 1,291 1,384 2,711 2,749
Restructuring charges and certain acquisition-related costs 190 [2] 478 [2] 787 [2] 1,368 [2]
Other deductions-net 664 423 2,321 1,255
Income from continuing operations before provision for taxes on income 4,484 [3] 3,598 [3] 6,919 [3] 6,608 [3]
Provision for taxes on income 1,290 1,077 2,001 1,951
Income from continuing operations 3,194 2,521 4,918 4,657
Discontinued operations-net of tax 66 [4] 97 [4] 145 [4] 195 [4]
Net income before allocation to noncontrolling interests 3,260 2,618 5,063 4,852
Less: Net income attributable to noncontrolling interests 7 8 16 20
Net income attributable to Pfizer Inc. $ 3,253 $ 2,610 $ 5,047 $ 4,832
Earnings per common share-basic:        
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.43 $ 0.32 $ 0.65 $ 0.58
Discontinued operations-net of tax (in dollars per share) $ 0.01 $ 0.01 $ 0.02 $ 0.02
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.44 [5] $ 0.33 [5] $ 0.67 [5] $ 0.61 [5]
Earnings per common share-diluted:        
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.42 $ 0.32 $ 0.65 $ 0.58
Discontinued operations-net of tax (in dollars per share) $ 0.01 $ 0.01 $ 0.02 $ 0.02
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.43 [5] $ 0.33 [5] $ 0.67 [5] $ 0.61 [5]
Weighted-average shares-Basic 7,476 7,875 7,506 7,929
Weighted-average shares-Diluted 7,537 7,935 7,570 7,980
Cash dividends paid per common share (in dollars per share) $ 0.22 $ 0.20 $ 0.44 $ 0.40
[1] Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
[2] From the beginning of our cost-reduction and transformation initiatives in 2005 through July 1, 2012, Employee termination costs represent the expected reduction of the workforce by approximately 60,000 employees, mainly in manufacturing and sales and research, of which approximately 47,900 employees have been terminated as of July 1, 2012. For the six months ended July 1, 2012, the increase represents additional accruals with respect to reserves for approximately 2,600 employees. The restructuring charges in 2012 are associated with the following: ● For the three months ended July 1, 2012, Primary Care operating segment ($35 million income), Specialty Care and Oncology operating segment ($16 million), Established Products and Emerging Markets operating segment ($1 million), Animal Health and Consumer Healthcare operating segment ($13 million), research and development operations ($13 million), manufacturing operations ($14 million) and Corporate ($59 million). ● For the six months ended July 1, 2012, Primary Care operating segment ($32 million income), Specialty Care and Oncology operating segment ($19 million), Established Products and Emerging Markets operating segment ($4 million), Animal Health and Consumer Healthcare operating segment ($18 million), research and development operations ($25 million), manufacturing operations ($166 million) and Corporate ($378 million). The restructuring charges in 2011 are associated with the following: ● For the three months ended July 3, 2011, Primary Care operating segment ($87 million), Specialty Care and Oncology operating segment ($7 million), Established Products and Emerging Markets operating segment ($12 million), Animal Health and Consumer Healthcare operating segment ($4 million), research and development operations ($51 million), manufacturing operations ($81 million) and Corporate ($24 million). ● For the six months ended July 3, 2011, Primary Care operating segment ($133 million), Specialty Care and Oncology operating segment ($42 million), Established Products and Emerging Markets operating segment ($15 million), Animal Health and Consumer Healthcare operating segment ($14 million), research and development operations ($473 million), manufacturing operations ($155 million) and Corporate ($135 million).
[3] Income from continuing operations before provision for taxes on income.
[4] Includes the Nutrition business for all periods presented and the Capsugel business for 2011 only.
[5] EPS amounts may not add due to rounding.